Why Pfizer and Moderna Could Soon Be Big Winners in a New $22 Billion Market
The late Sen. Everett Dirksen from Illinois was credited with saying, "A billion here, a billion there, and pretty soon you're talking real money." Whether or not he actually said those exact words, Dirksen would probably agree that Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) are swimming in real money these days thanks to their COVID-19 vaccines.
Pfizer expects that the COVID-19 vaccine that it markets with partner BioNTech will generate sales of around $26 billion this year. Based on its advance purchase agreements in place as of March 31, Moderna anticipates that its COVID-19 vaccine will rake in sales of more than $19 billion.
It's quite possible, though, that both of those sales projections could be way too pessimistic. Here's why Pfizer and Moderna could soon be big winners in a new $22 billion market.
Source Fool.com
